Plus, who should be on alert.
After 11Alive uncovered unusually high thyroid cancer rates in five northeast Georgia counties, new research is underway to ...
A thyroglobulin of 2.5 ng/mL or less may not be enough to determine cancer remission for adults with low-intermediate- or ...
A Class I recall of a thyroid medicine is causing confusion and concern among the many Americans who use such medications.
The recalled tablets from Vitruvias Therapeutics, Inc. are “superpotent,” the company said, meaning they are stronger than expected ...
The FDA on Sept. 22 classified the recall of one lot of Vitruvias Therapeutics' 30 mg thyroid tablets as Class I, its highest risk level ...
An updated guideline proposed several shifts in how healthcare professionals manage thyroid health for pregnant women.In May, ...
A recalled thyroid medicine has been classified under the FDA's most serious risk level, indicating it could potentially be deadly.
Vitruvias advised patients taking tablets from the affected lot to contact their health care provider before stopping the medication and to seek guidance or ...
The supplemental indication for satralizumab, already sold for a rare neuroinflammatory disease, is another example of the recent marked growth in approved treatments for thyroid eye disease.
A comprehensive scoping review of 78 published cases reveals how often cardiac arrest complicates thyroid storm and raises ...
Liza M. Cohen, MD, explains when to use CT vs MRI in thyroid eye disease and why to review images yourself.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results